ARS Pharmaceuticals, Inc. (SPRY) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-09
Business type: Asset play
How it makes money
It sells needle-free epinephrine to patients, earning revenue when insurers and patients pay for this specific delivery method over traditional injectable autoinjectors.
Profitability is primarily driven by the adoption of its needle-free spray among the estimated 3.2 million patients who currently fill prescriptions. Success depends on converting these patients from standard autoinjectors, which requires securing broad insurance coverage and maintaining favorable gross-to-net pricing yields.
What protects it: the moat
It relies on its unique FDA-approved needle-free delivery method to differentiate itself from incumbent injectable epinephrine products.
The company asserts a competitive advantage through its proprietary Intravail absorption technology, which is the foundation of its regulatory approval. It claims this first-in-35-year innovation creates a distinct product category.
What growth costs
It must fund a large, specialized sales force and aggressive direct-to-consumer marketing to drive physician adoption and patient awareness.
Growth requires constant reinvestment in its 106-person sales team, expanded co-promotion agreements, and expensive media campaigns to overcome existing habits of prescribing injectable devices. The company does not specify the exact split between maintaining and growth spending, noting only that building these capabilities is inherently expensive and time-consuming.
What could damage it
Failure to secure and maintain insurance coverage would render the product unaffordable, causing revenue to collapse regardless of physician interest.
If payors determine that the product's cost is not justified relative to cheaper legacy autoinjectors, they may deny coverage or mandate high prior-authorization barriers, preventing patient access and destroying the company's sole revenue stream.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.